The management at OurPet’s Company (OTCQX: OPCO) is driven by animal spirits. They’ve taken the quite mundane business of pet care and turned it into a high tech, high touch enterprise. Products now range from the groundbreaking OurPets® Big Dog Feeder® (http://dtn.fm/hG4WS) to the Intelligent Pet Care™ line (http://dtn.fm/dK3Al), which uses digital technologies to enhance communication with pets. In an industry that is growing twice as fast as the economy, OurPet’s Company is racing ahead at double the industry pace. In its third quarter 10-K, published November 14, 2016, the company shows that this pace has not lessened. Revenues for 2016 through the first three quarters were about 10% greater than for the same period a year ago.

When, in 1936, John Maynard Keynes coined the term ‘animal spirits’ in his magnum opus “The General Theory of Employment, Interest and Money”, he was describing the ‘spontaneous optimism’ on which ‘a large proportion of our positive activities depend’. The great man opined that ‘if the animal spirits are dimmed and the spontaneous optimism falters, leaving us to depend on nothing but a mathematical expectation, enterprise will fade and die’. In other words, however businesslike we may consider ourselves to be, in the end, we are irrational creatures, moved by sentiment and plagued by lack of information.

The animal spirits driving OPCO are not just pie in the sky, however. They are grounded in ‘mathematical expectation’, as the company’s latest quarterly report indicates. Net revenue for the nine months to September 2016 was $18.9 million, increasing by about $1.7 million over same period sales the year before. Net revenue for the third quarter of 2016 was $7.3 million, 21 percent higher than third quarter 2015 revenue of $6.0 million. Income after taxes for the nine-month period was also about 21% higher than the year before, and diluted earnings per share rose from $0.04 to $0.05.

OPCO continues its marketing focus on the pet specialty; food, drug and mass retail; and e-commerce distribution channels. Third quarter sales to pet specialty customers accounted for 48 percent of the company’s total, while mass retail sales and e-commerce sales made up 39 percent and eight percent, respectively. The other five percent of sales took place mostly through the value and closeout channels.

The strategy to implement a renewed marketing push was set in motion last year, when OPCO initiated its dual-branding approach. The OurPets® brand is targeted at the pet specialty channel, while the Pet Zone brand is sold to the food, drug and mass retail channel. Both brands are sold online through the company’s e-commerce effort.

Pet care is becoming big business as Americans lavish care and attention on their animals. The industry is expected to grow to almost $63 billion by the end of 2016. If pet care were a country, it would rank around #70 in economic size out of 196 economies. That, maybe, accounts for the animal spirits at OurPet’s Company.

For more information, visit the company’s website at www.OurPets.com

Let us hear your thoughts: OurPet’s Co. Message Board

Cellceutix (OTCQB: CTIX) CEO Leo Ehrlich in September issued a fiscal year-end business statement recapping the company’s ability to usher its three unique compounds through various stages of clinical trials to successfully meet primary endpoints and drop anchors in several key markets. Advancements of its current pipeline – spanning dermatology, cancer, infectious disease and gastrointestinal indications – also set the company on course to achieve another season of remarkable progress.

Cellceutix’s lead cancer drug candidate is Kevetrin™, an Orphan Drug anti-cancer agent entering phase 2a clinical trials for the treatment of ovarian cancer. Upon commercialization, Kevetrin would be the world’s first p53-modulating drug. The company is also conducting research to develop an oral formulation of Kevetrin, taking advantage of the drug’s short half-life of roughly two hours.

“If we can develop an oral Kevetrin dosing possibilities are numerous. Perhaps two times or three times a day and seven days a week. Now you know why we are excited. A drug activating p53 and dosed orally, we think would have blockbuster potential. More research needs to be done to validate the clinical effectiveness of Kevetrin as well as developing an oral formulation. But I’d hope investors now understand why we get excited about the possibility of developing both the world’s first safe p53 modulating drug and an oral formulation,” Ehrlich stated in the company’s fiscal Q1 2017 earnings call in September (http://dtn.fm/2l0JR).

Another propellant of progress is an anti-psoriasis drug candidate the company once called a “dark horse” or “long shot.” Advancing through two successful clinical trials, however, the potential of Cellceutix’s Prurisol™, now in phase 2b trials, is starting to take shape.

“We believe that the potential safety profile of Prurisol may make this an attractive alternative to Celgene’s (NYSE: CELG) OTEZLA, which is on its way to achieving $1 billion in sales within just three years of its launch,” Arthur P. Bertolino, MD, PhD, MBA, president and chief medical officer at Cellceutix, stated in a recent news release.

In the previously mentioned September business update, Ehlrich also noted Allergan’s (NYSE: AGN) $639 million acquisition of Vitae Pharmaceuticals’ (NASDAQ: VTAE) two clinical drug candidates, one of which is an oral therapy for psoriasis (http://dtn.fm/JJ3mQ).

“I share this with you because it exemplifies the premium that the industry is placing on new, oral psoriasis drugs, even those in mid-stage development. I’m not in the business of analysis, but it seems to me that Allergan values VTP-43742 at more than our total market capitalization. As such, we see a tremendous market opportunity with Prurisol and greatly look forward to initiating our Phase 2b trial in patients with moderate to severe psoriasis with emphasis on the Psoriasis Area and Severity Index (PASI). We’ve just advanced substantial start-up payments to vendors towards the trial, an action that we feel will continue to grow shareholder value.

“I wish to point out that Dr. Bertolino is now introducing Prurisol to large pharmas, most of which are embracing it for the first time. We believe that the path to a large financial deal is generation of comparably encouraging data in Phase 2b as recently seen in our completed Phase 2a trial,” he said.

Interim analysis of top-line phase 2b results of Cellceutix’s study is expected in the second quarter of 2017.

The third candidate in the pipeline is Brilacidin, which has shown antibacterial, anti-biofilm and anti-inflammatory properties in various pre-clinical studies. Currently underway is a phase 2 trial evaluating the oral rinse Brilacidin-OM for the treatment of chemoradiation-induced oral muscositis (OM), an inflammatory condition, in head and neck cancer patients.

“Having data, demonstrating Brilacidin can fight inflammation and doesn’t accumulate in the blood is a major benefit for what can be a painful and expensive condition that doesn’t have any FDA approved treatments. We greatly look forward to additional data from this trial expected in the first half of 2017,” said Ehrlich.

Cellceutix’s pursuit of FDA approval for the products in its pipeline is piquing the interest of larger peers, according to Ehrlich, which in recent months has resulted in more “high-level” business development meetings than at any other time in the company’s history.

“Over the years we have gone from a company with only a single lead drug candidate in an early clinical study to a company that has effectively has three lead drug candidates at mid-state trials targeting multiple indications with new possibilities cropping up regularly underscored by our robust pipeline. We’re having success at targeting multi-billion dollar opportunities with new drugs that can provide relief for millions of people worldwide suffering from hard-to-treat maladies. I believe that is more than ample reason to be excited about all that we have accomplished our future and the litany of catalyst expected in 2017,” said Ehrlich.

For more information, visit the company’s website at www.cellceutix.com

Before the opening bell, Singlepoint, Inc. (OTC: SING) issued an update on the corporate initiatives being taken by its SingleSeed subsidiary in order to better position itself in the growing domestic cannabis industry. Following November’s vote, more than half of all U.S. states have now legalized marijuana for either recreational or medicinal purposes, leading to a figurative ‘green rush’ comprised of businesses seeking to capitalize on the emergence of the industry. SingleSeed, in particular, is focused on providing improved access to electronic payment options for dispensaries and similar businesses. Although banking is currently highly restricted based on federal regulations regarding the legality of marijuana, Singlepoint’s management team forecasts a shift in the coming months, as more financial institutions begin to pursue ways to work with cannabis businesses moving forward.

“With the 2016 elections behind us, the favorable outcome for the cannabis industry has opened a floodgate of opportunity for cannabis merchants, consumers, and companies providing much-needed industry services, such as those offered by SingleSeed,” Singlepoint CEO Greg Lambrecht stated in this morning’s news release.

Originally reawakened from a quiet period in early November, SingleSeed is currently focused on providing credit card processing solutions for the legal cannabis industry. In an interview with Donald Baillargeon released late last week, Lambrecht offered prospective shareholders some additional insight into these efforts. Since announcing the reawakening of SingleSeed, Singlepoint has been “inundated with calls from dispensaries,” according to Lambrecht. While the company awaits a decision from the incoming administration that provides a long-term solution to the cannabis industry’s banking problem, SingleSeed is building a database of potential clients in the space that will likely give it a strategic advantage after the current banking woes are addressed.

“Additionally, we are already receiving significant demand from dispensaries asking for our payment solutions,” Lambrecht concluded. “We are excited that our fast-paced progression is well-aligned with market demand as we pursue and act on opportunities to capitalize on this billowing market.”

Although its options are currently extremely limited regarding electronic payments in the cannabis industry, Singlepoint is taking a proactive approach toward establishing a position in the burgeoning space. The company is currently in the process of revamping the SingleSeed website in order to better serve potential cannabis industry clients. Additionally, Singlepoint is making its existing text message marketing program available to dispensaries, allowing these businesses to better communicate with their members while experiencing the strategic benefits offered through maintaining a relationship with SingleSeed.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

Cancer is the great scourge of our age. This year, 1.7 million Americans will find out they have the disease and some 600,000 will die from it. In total, approximately 40 percent of the population can expect to be diagnosed with cancer during their lifetime. The name “cancer” is derived from the Greek word for crab and may have been bestowed to indicate the tenacity of the disorder. Cancer tends to persist with the same relentlessness as the claws of a crab cling to a victim.

Yet despite its stubbornness, cancer treatments like chemotherapy have reduced fatalities. Cancer is a formidable foe, however, and the fight against it often leads to a Pyrrhic victory. Patients are left seriously debilitated. Now, SUSTOL® (granisetron) from Heron Therapeutics (NASDAQ: HRTX) is available to provide extended relief to chemo patients suffering from Chemotherapy-Induced Nausea and Vomiting (CINV).

About four million people worldwide receive chemotherapy, making it the most common treatment for cancer, but chemo comes with a number of pernicious side effects, one of which is CINV. Cancer patients identified CINV as the side effect of chemo they most wanted to avoid, ahead of depression, constipation, fatigue, diarrhea and sexual dysfunction. The abhorrence to CINV is thought to be the main reason leading to premature discontinuation of remedial chemo regimens.

Chemotherapy agents that give rise to the most intolerable bouts of nausea and vomiting are grouped as either Moderately Emetogenic Chemotherapy (MEC) or Highly Emetogenic Chemotherapy (HEC). About 30-90 percent of patients undergoing MEC treatments and more than 90 percent of those undergoing HEC ones experience vomiting without preventative treatment. Overall, some 70-80 percent of chemo patients experience CINV. These numbers show promising market potential for SUSTOL®.

SUSTOL® was launched in October and is the first and only approved
5-HT3 receptor antagonist offering an extended-release effect and five days of
CINV prevention for MEC and HEC regimens. The 5-HT3 receptor system regulates the body’s emetic (nausea and vomiting) responses. SUSTOL® has two important advantages over the market leader, Aloxi. First, it offers a true extended five-day release, as opposed to Aloxi, which drops off after three to four days, a period considered too short for most MEC and HEC regimens. Second, it has a higher profitability potential for oncologists. Over the past three and a half years, Aloxi has had unit sales in the U.S. of between 600,000-700,000 vials per quarter. Aegis Capital (http://dtn.fm/f2EEv), in a recent report, opines that ‘SUSTOL® represents at least a $300 million opportunity over the next five years’.

There’s more to Heron than SUSTOL®, however. The company’s present pipeline includes HTX-011 and HTX-019. HTX-011 is being tested for post-op pain in nerve block and post-op pain in local administration. HTX-019 is being evaluated for the treatment of CINV.

SUSTOL® and HTX-011 utilize Heron’s proprietary Biochronomer® drug delivery technology, which can deliver therapeutic levels of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection. The Biochronomer® technology consists of bio-erodible polymers, which comprehensive animal and human toxicology studies have established to be safe and well tolerated. When injected into subcutaneous tissue, the polymers undergo controlled hydrolysis, resulting in a controlled, sustained release of the pharmacological agent encapsulated within the Biochronomer-based composition.

Aegis has set a ‘Buy’ rating and a price target of $41.00 on Heron stock, which is currently trading on the NASDAQ under the symbol HRTX at around $15.50.

For more information, please visit www.herontx.com

Neuralstem, Inc. (NASDAQ: CUR) is a biotechnology company whose patented technology allows for the production, on a commercial level, of a number of types of central nervous stem cells. These are in the development stage for the treatment of conditions and diseases of the central nervous system. The company recently announced the start of enrollment of patients for its phase II trial of NSI-189, a drug developed after Neuralstem did research into neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of neurons.

On November 7 of this year, Aegis Capital Corp. (http://dtn.fm/ep5M8) initiated coverage on Neuralstem, Inc., offering the company a 12-month target price of $2.25 with investment highlights including the enrollment of its phase II trial for NSI-189, the investment of $20 million from Tianjin Pharmaceuticals Holdings Group for completion of the phase II trial, the development of a stem cell platform, and its strong cash position.

Later, on November 10, 2016, Aegis Capital Corp. (http://dtn.fm/hF8ex) released an update to the report, reiterating the company’s ‘Buy’ rating and target price of $2.25 due to the release of Neuralstem’s quarterly results and the update on NSI-189. The company ended the third quarter of 2016 with $5.7 million in cash and cash equivalents with additional proceeds of $20 million from Tianjin Pharmaceuticals Holding Group being used mainly for the future development of NSI-189, the upcoming clinical trial for which is over 50% enrolled and is expected to deliver results as early as 2017.

Aegis Capital Corp. is not the only research analysts firm to take an interest in CUR. According to an article by Cerbat Gem Market News and Analysis (http://dtn.fm/YWjF2), a number of equities research analysts undertook coverage of the company, offering a similar ‘Buy’ rating. Brean Capital offered the company a target price on shares at $4.00 and Roth Capital set the company’s target price on shares at $1.20.

The article also pointed out that numerous hedge funds and other investors have modified their stakes in the company. Sabby Management LLC and Blair Williams & Co. both purchased new positions in CUR worth approximately $1.8 million and $122,000, respectively. CEO Richard J. Daly bought over 35,000 shares of the company worth just under $29,000. In addition, Vanguard Group, Inc. increased its position in shares by over 21%, giving the group ownership of over three million shares worth just under $1 million. Neuralstem is currently trading near $0.27 per share.

For more information, visit the company’s website at www.neuralstem.com

A leading provider of mobile technology and mobile payment solutions serving various markets and industries, Singlepoint, Inc. (OTC: SING) has its eyes set on the fast-growing cannabis industry, aiming to help legal marijuana businesses build trust and increase customer loyalty via subsidiary SingleSeed and its highly reliable payment processing and marketing tools.

With eight more states voting to legalize either medical or recreational marijuana use last month, the marijuana industry is set to exceed $7 billion this year and to reach roughly $20 billion by 2020. However, legal businesses operating in the sector still find it hard to obtain support from banking and financial institutions, given that marijuana is still considered an illegal drug by the federal government. Singlepoint’s SingleSeed subsidiary is looking to change this, and it is ready to offer retail or medical marijuana merchants the tools they need to grow their businesses safely and securely.

SingleSeed was only recently relaunched, with the specific purpose of providing non-cash payment solutions and mobile marketing tools to an industry that badly needs them. The company’s three main services – Cashless ATM, Pay by Text™, and Text Message Marketing, are each designed to help clients operate more efficiently by accepting electronic payments, growing their customer base and improving communication.

Text Message Marketing, in particular, was designed with the specific purpose of helping merchants build trust by keeping in contact with their customer base and developing a solid, trust-based relationship with clients. The app allows marijuana business owners to connect to their target audiences, including potential and existing clients, easier and faster than ever before. Relying heavily on text messaging, which is a very effective strategy for maintaining a customer relationship, especially with the fast-growing Millennial market, this app is built around the idea of sending customers texts and information that are timely and relevant to them. By offering customers something that they cannot get elsewhere, they will keep coming back, according to SingleSeed.

Marijuana businesses using this service should expect increased customer loyalty, as the text messaging system allows them to reach their target audiences instantly, given that 97 percent of all text messages are read within 15 minutes of receipt, while driving increased sales as a consequence of sending daily promotions and deals or discount coupon codes via text and ensuring use of the right voice when communicating with customers, all with the help of the program’s integrated compliance platform.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

A legal dispute with the European Patent Office over the European patent for its lead product candidate surprisingly presents a strong buying opportunity for clinical stage biopharmaceutical company Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR), according to an analysis report (http://dtn.fm/9UkRd) released by Aegis Capital Corp on November 23. As such, Aegis analysts reiterated a ‘Buy’ rating for the company and proposed a higher stock price target of $41, compared to the $25.28 stock price at the time the report was issued.

The report acknowledges that the ruling by the European Patent Office’s Opposition Division is unfavorable to product candidate ALD403 and a setback for Alder Biopharmaceuticals and Eli Lilly and Company (NYSE: LLY) in their intellectual property legal proceedings. However, Aegis analysts view the decision as a buying opportunity for Alder, as the valuation impact to the company is minimal. Since the primary market for ALD403, a promising innovative product for migraine prevention and treatment, is still the United States, the European Patent Office ruling is unlikely to have a major impact, the Aegis report says, estimating only an approximate $2 per share decrease from its expected target price.

The dispute stems from opposition to a European patent filed for ALD403 by Alder and Eli Lilly back in July 2014. The European Patent Office’s Opposition Division on November 18 of this year issued an oral ruling unfavorable to the product, insisting that the entire patent should be revoked because it puts forth claims that are too broad and go beyond what is allowed under the European Patent Convention. The patent in question initially claimed proprietary rights over the use of calcitonin gene-related peptide (CGRP) antibodies in therapies designed to prevent vasomotor symptoms associated with CGRP. In the meantime, it has been amended heavily to cover only narrower claims over the use of CGRP antagonist antibodies for the treatment and prevention of headaches, such as migraines and cluster headaches.

The European Patent Office’s Opposition Division’s written ruling is expected in the following weeks. In the meantime, Alder and Eli Lilly already have plans to file an appeal against the decision, based on their initial argument that the broad claims the European Patent Office granted originally should not have been allowed and therefore should be revoked entirely. According to the Aegis Capital Corp report, it’s very likely that the Technical Board of Appeal of the European Patent Office will not uphold the initial ruling of the Opposition Division, since the original claims made by the patent were indeed too broad and went against European Patent Convention provisions and requirements.

Regardless of the outcome, the Aegis report notes, it is unlikely to impact Alder’s U.S. business, given the substantial patent system differences between the United States and the European Union. So even if Alder loses the European Patent Office Case, this will not block the company’s right to move forward with ALD403 clinical development and eventual commercialization in the U.S.

The Aegis Capital Corp report also reiterated a ‘Buy’ rating with a stock price target of $41 for Alder and identified a series of potential risks for investors, including typical risks associated with investments into pre-clinical healthcare development companies (regulatory, research and development, commercialization and manufacturing) and specific risks associated with investing in Alder Biopharmaceuticals (intellectual property rights over ALD403, binary events related to the company’s development programs, the company showing no history of profitability and the possibility of needing more funds to commercialize its products).

For more information, visit the company’s website at www.alderbio.com

Before the opening bell, Singlepoint, Inc. (OTC: SING) was announced as a featured company on this week’s episode of MoneyTV with Donald Baillargeon. MoneyTV is an internationally syndicated television program about “money and what makes it happen.” The show includes informative interviews with company CEOs, offering prospective investors insight into their operations and outlooks for the future.

To view this week’s program, visit www.MoneyTV.net

In the interview, Greg Lambrecht, chief executive officer of Singlepoint, offered prospective investors an update on the progress of the company’s SingleSeed subsidiary, which it awakened from a quiet period in early November in an effort to capitalize on the emergence of the multi-billion dollar cannabis industry. Despite the hesitance of financial institutions to work with legal cannabis companies across the country, recent election results and a nationwide shift in attitudes toward marijuana legalization has dispensaries and other businesses optimistic about the possibility of electronic payment acceptance in the near future.

“We have been inundated with calls from dispensaries that have seen our different press releases and announcements that we’re getting back into merchant processing for the cannabis business,” Lambrecht stated in the interview. “We’ve had a lot of demand. Of course, we’ve had to tell them that we’re taking their name and number and email and putting them on the list. We’re very excited about demand.”

While politicians continue to grapple over a solution to the marijuana banking conundrum, Singlepoint is taking proactive steps to better capitalize on its first-mover advantage in the space. The company is currently offering marketing services to businesses operating in the cannabis industry, which allows Singlepoint to both commercialize its existing text message marketing solutions and expand its reach in the burgeoning space ahead of an anticipated policy shift.

“One of the things that we’re actively doing to get ahead of the curve here is we’re totally revamping our SingleSeed website, which is for the cannabis business, and really activating it,” continued Lambrecht. “We’re going to allow these dispensaries to use our text message marketing program, which is legal, and they can get started on now to communicate with their members. They’ll be able to go to the site to sign up, not only for that, but also to get a terminal in the future.”

Lambrecht concluded the interview by looking forward to 2017. Referencing the policy of President-elect Donald Trump regarding the rights of individual states to decide on marijuana legalization, Lambrecht and host Donald Baillargeon agreed that the time for a long-term solution to the cannabis industry’s banking woes is fast approaching, potentially occurring as soon as the first quarter of next year. With this forecast in mind, Lambrecht spoke to the strategic positioning of Singlepoint as a leading payment processing option for cannabis dispensaries and other businesses operating in the industry.

“We have an extreme first-mover advantage over other companies to be the one to handle their merchant processing,” he concluded.

For more information, visit the company’s website at www.Singlepoint.com

Let us hear your thoughts: Singlepoint, Inc. Message Board

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) is a biotechnology company focused on the development of generic versions of complex drugs. The company is in the business of discovering and developing new therapies for oncology and autoimmune indications. Currently, the company has four products still in the development stage (hsIVIg, M230, five biosimilar programs, and M834), two in clinical stage one trials (M281 and M923), one in the process of being BLA and NDA accepted (40 mg/ml COPAXONE®), and two already being sold at market (LOVENOX® and 20 mg/ml COPAXONE®).

Most recently, the company announced positive top-line phase III results for M923, a biosimilar HUMIRA® which is used in patients with moderate to severe chronic plaque psoriasis. Out of all the subjects who took part in the study, 75% showed a reduction in the psoriasis area and the severity index (PASI-75) was equal between both M923 and HUMIRA® after the 16-week treatment. Although the drug has been developed and commercialized by both MNTA and Baxter Bioscience, now part of Shire, MNTA is expected to take over M923 in order for Shire to continue its focus on treating patients with rare diseases.

Aegis Capital Corp. (http://dtn.fm/b20Re), initiated coverage on the company on November 22, 2016, giving MNTA a ‘Hold’ rating with a price target of $15 based on the fact that the commercial launch of 40 mg Glatopa (a generic equivalent of COPAXONE®) is not expected for 2017 and that phase III trial results had not yet been disclosed. With these now showing promising results, it is worth noting that Aegis Capital Corp. stated, “If positive the M923 timeline has the potential to include a submission for marketing approval around mid-2017”.

According to Baseball News Source (http://dtn.fm/Pat6b), Momenta Pharmaceuticals, Inc. has been on the radar for many analysts, receiving a consensus rating of ‘Buy’ from the 10 analysts covering the stock. The average price target from brokers for the next year is $16, with one research analyst giving the company a ‘Sell’ rating, three giving it a ‘Hold’ rating, and six offering a ‘Buy’ recommendation. Analysts included Stifel Nicolaus, Maxim Group, Zacks Investment Research, Cowen and Company, and Aegis Capital Corp., among others.

In addition to the above, a number of investors have recently changed their stakes in the company’s stock. Pacad Investment Ltd., Jane Street Group LLC, Dynamic Technology Lab Private Ltd., Profund Advisors LLC, and Cornerstone Capital Management Holdings LLC acquired new stakes in Momenta Pharmaceuticals, Inc., all of which were worth more than $100,000 individually. Hedge funds and investors now own approximately 85% of MNTA’s stock.

Momenta reported its financial results for the nine months ended September 30, 2016 early last month. For the nine-month period, the company reported total revenue of just over $75 million, which included just under $59 million in revenues from Sadoz’s sale of Glatopa®. Recently, the company traded up by more than 0.70%, reaching $14.15 per share. As of the end of September, Momenta had cash and cash equivalents of $309 million. The company has a market cap of $975.74 million with revenue up 2067.7%, as compared to the same time last year.

For more information, visit the company’s website at www.momentapharma.com

Diagnostic labs and drug developers are in a constant search for cheaper, better, faster test results, and SQI Diagnostics (OTCQX: SQIDF) is focused on meeting this demand. The company reduces the timeline for urgently-needed test results and the amount of labor needed, all without forfeiting quality.

SQI Diagnostics is a life sciences and diagnostics company that supports better health care through the development and marketing of technologies and products that propel faster and more accurate advanced multiplexing diagnostics. From SQI’s base in Toronto, a team of expert scientists develops custom research and diagnostic assays that are multiplexed to consolidate and automate many individual tests into one.

The company’s portfolio of automated systems and platforms includes:

• sqidworks diagnostic platform, a fully-automated microarray processing and analytical system;
• sqidlite bench-top diagnostic system, a fully automated bench top microarray processing system; and
• sqid-X, a semi-automated bench-top platform.

SQI delivers these market-leading, quality tests and automated systems for customers who need to measure a broad range of biomarkers in blood and/or other common sample types. Its team supports these customers, who have the skills and ideas to considerably improve quality of life, by providing the tools and services that will bring those ideas to the market sooner.

SQI has 12 patents and the knowledge base to simplify the multiplex testing needs of three key markets, including pharmaceutical and biotechnology drug development, human diagnostic testing and animal health diagnostic testing.

The company’s multiplexed tests and automated systems, combined with its full service product commercialization, hands-free processing and automated data analysis and reporting, shorten the work flow for these markets. This way, the SQI team assists in generating more comprehensive data. By delivering many diagnostic results from single tests and single specimens while using an automated process, SQI increases sample throughput; reduces time, cost and chance for human error; and provides excellent data quality.

To take a closer look at this company, visit www.sqidiagnostics.com